Skip to content

US · BWAY · MEDICAL - DEVICES

BrainsWay Ltd. (BWAY) intrinsic value and stock valuation

$8.48as of 2026-11-21 · Mkt cap 607.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BrainsWay Ltd. DCF and intrinsic value

InvestorsCraft values BWAY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BWAY’s statements →

BrainsWay Ltd. Graham Number

Graham Number: $5.88d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Jerusalem, JM 9777518 brainsway.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$52.2M+18.8% 5y CAGRd
20122025
Net income
$7.63M
20122025
Free cash flow
$16.4M
20122025
Total equity
$73.2M+30.1% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$52.2M$41M$31.8M$27.2M$29.7M
Operating income$4.32M$1.39M-$-4.96M-$-12.68M-$-5M
Net income$7.63M$2.92M-$-4.2M-$-13.35M-$-6.46M
EPSd$359.7K$84K-$-126.66K-$-404.79K-$-207.38K
Operating cash flow$18.2M$10.3M$1.28M-$-9.76M$880K
Capital expenditure-$-1.76M-$-3.79M-$-2.39M$9.72M-$-2.24M
Free cash flow$16.4M$6.5M-$-1.1M-$-9.76M-$-1.35M
Total assets$112.9M$94.3M$63M$64.5M$75.7M
Total debt$6.82M$5.62M$470K$490K$750K
Net debt-$-60.88M-$-63.72M-$-10.05M-$-47.09M-$-16.17M
Total equity$73.2M$62.3M$41.6M$45.4M$57.3M
Cash and short-term investments$69.1M$69.3M$46M$47.6M$57.4M
Income statement
20252024202320222021
Revenue$52.2M$41M$31.8M$27.2M$29.7M
Cost of revenue$12.8M$10.4M$8.31M$7.13M$6.6M
Gross profit$39.4M$30.6M$23.5M$20.1M$23.1M
Research and development expenses$9.6M$7.19M$6.67M$7.68M$6.39M
Selling, general and administrative expenses$25.5M$22M$21.6M$25.1M$21.7M
Other expenses$0.00$0.00$130K$0.00$0.00
Operating expenses$35.1M$29.2M$28.4M$32.7M$28.1M
Cost and expenses$47.9M$39.6M$36.7M$39.9M$34.7M
Interest income$5.64M$2.48M$2.17M$1.11M$230K
Interest expense$2.23M$1.36M$300K$70K$140K
Depreciation and amortization$1.54M$1.77M$1.34M$1.53M$1.69M
Ebitda$11.5M$5.36M-$-2.56M-$-11.45M-$-4.67M
Operating income$4.32M$1.39M-$-4.96M-$-12.68M-$-5M
Total other income/expenses, net$3.39M$2.07M$1.01M-$-350K-$-1.42M
Income before tax$7.71M$3.46M-$-3.95M-$-13.03M-$-6.42M
Income tax expense$80K$540K$250K$320K$40K
Net income$7.63M$2.92M-$-4.2M-$-13.35M-$-6.46M
Weighted average shares outstanding$19.1M$34M$33.2M$33M$31.2M
Weighted average diluted shares outstanding$21.2M$34.8M$33.2M$33M$31.2M
Balance sheet
20252024202320222021
Cash and short-term investments$69.1M$69.3M$46M$47.6M$57.4M
Net receivables$4.11M$4.6M$3.78M$4.84M$6.33M
Inventory$7.13M$4.43M$3.72M$3.84M$200K
Total current assets$84.9M$79.7M$55.5M$58.1M$65.5M
Property, plant and equipment, net$12.2M$12M$5.79M$5.35M$9.33M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$14.3M$0.00$0.00$0.00$0.00
Total non-current assets$28M$14.7M$7.51M$6.39M$10.3M
Total assets$112.9M$94.3M$63M$64.5M$75.7M
Accounts payable$2.43M$2.87M$760K$1.12M$1.1M
Short-term debt$1.07M$820K$230K$230K$500K
Deferred revenue$12.2M$5.73M$3.51M$1.48M$2.19M
Total current liabilities$22.2M$15.4M$9.76M$8.14M$9.07M
Long-term debt$5.74M$4.8M$240K$250K$250K
Deferred revenue, non-current$11.8M$9.43M$5.31M$4.67M$3.16M
Total non-current liabilities$17.5M$16.7M$11.6M$10.9M$9.34M
Capital lease obligations$6.82M$5.62M$470K$490K$750K
Total liabilities$39.7M$32M$21.4M$19.1M$18.4M
Common stock$430K$410K$370K$360K$360K
Retained earnings-$-90.75M-$-98.38M-$-101.3M-$-97.11M-$-83.76M
Accumulated other comprehensive income (loss)-$-2.19M-$-2.19M-$-2.19M-$-2.19M-$-2.19M
Total equity$73.2M$62.3M$41.6M$45.4M$57.3M
Total investments$15.8M$0.00$35.5M$0.00$40.4M
Total debt$6.82M$5.62M$470K$490K$750K
Net debt-$-60.88M-$-63.72M-$-10.05M-$-47.09M-$-16.17M
Cash flow statement
20252024202320222021
Net income$7.63M$2.92M-$-4.2M-$-13.35M-$-6.46M
Depreciation and amortization$1.54M$1.77M$1.34M$1.53M$1.69M
Stock-based compensation$1.2M$1.44M$380K$1.47M$1.89M
Change in working capital$8.23M$2.39M$1.64M-$-1.45M$1.07M
Accounts receivable$610K-$-870K$1.09M$1.46M-$-850K
Inventory-$-1.41M-$-920K-$-510K-$-3.6M-$-410K
Accounts payable-$-480K$2.12M-$-330K$0.00$290K
Net cash provided by operating activities$18.2M$10.3M$1.28M-$-9.76M$880K
Investments in property, plant and equipment-$-1.76M-$-4.76M-$-2.39M$1.94M-$-2.24M
Acquisitions, net$0.00$0.00$0.00$0.00$40M
Net cash used for investing activities-$-17.63M$30.3M-$-37.41M$42.2M-$-42.22M
Common stock issued$0.00$16.4M$0.00$0.00$42.3M
Common stock repurchased$0.00$0.00$0.00-$-50K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-2.23M$18.3M-$-1.03M-$-1.55M$41.5M
Net change in cash-$-1.67M$58.8M-$-37.06M$30.7M-$-40K
Cash at end of period$68M$69.3M$10.5M$47.6M$16.9M
Operating cash flow$18.2M$10.3M$1.28M-$-9.76M$880K
Capital expenditure-$-1.76M-$-3.79M-$-2.39M$9.72M-$-2.24M
Free cash flow$16.4M$6.5M-$-1.1M-$-9.76M-$-1.35M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BrainsWay Ltd.

        BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

        CEO
        Hadar Levy
        Employees
        129
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of BrainsWay Ltd. (BWAY)?

        InvestorsCraft does not currently publish an intrinsic value for BWAY. How the IC value is calculated.

        Is BWAY undervalued?

        InvestorsCraft does not publish an undervaluation signal for BWAY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.